ʻO Polysaccharide mai Chlorella (PFC), ma ke ʻano he polysaccharide maoli, ua huki nui ʻia e ka poʻe loea i nā makahiki i hala aku nei ma muli o kāna mau pono o ka haʻahaʻa haʻahaʻa, nā hopena haʻahaʻa, a me nā hopena ākea ākea. ʻO kāna mau hana i ka hoʻohaʻahaʻa ʻana i nā lipids koko, anti-tumor, anti-inflammatory, anti Parkinson's, anti-aging, etc. Eia nō naʻe, aia nō kahi āpau i ka noiʻi ʻana ma ka PFC ma ke ʻano he modulator immune kanaka.

ʻO nā pūnaewele dendritic (DCs) nā pūnaewele hōʻike antigen kūikawā ikaika loa i ke kino o ke kanaka. He liʻiliʻi loa ka helu o nā DC i loko o ke kino kanaka, a ua hoʻohana mau ʻia kahi cytokine i hoʻopili ʻia i loko o ka vitro induction model, ʻo ia hoʻi ke kanaka peripheral blood mononuclear cell-derived DCs (moDCs). Ua hōʻike mua ʻia ke kumu hoʻohālike in vitro induced DC i ka makahiki 1992, ʻo ia ka ʻōnaehana moʻomeheu kuʻuna no DC. ʻO ka maʻamau, pono ia i ka mahiʻai no 6-7 mau lā. Hiki ke hoʻoulu ʻia nā pūnaewele iwi ʻiole me ka granulocyte macrophage colony-stimulating factor (GM-CSF) a me interleukin (IL) -4 no ka loaʻa ʻana o nā DC oʻo ʻole (hui PBS). Hoʻohui ʻia nā cytokines e like me nā mea hoʻoulu a hoʻoulu ʻia no nā lā 1-2 e loaʻa ai nā DC oʻo. Ua hōʻike ʻia kahi noiʻi ʻē aʻe ua hoʻomaʻemaʻe ʻia nā cell CD14 + kanaka i hoʻomaʻemaʻe ʻia me interferon - β (IFN - β) a i ʻole IL-4 no 5 mau lā, a laila moʻomeheu ʻia me ka tumor necrosis factor-a (TNF-a) no 2 mau lā e loaʻa ai nā DC me ke kiʻekiʻe. hōʻike o CD11c a me CD83, nona ka mana ikaika e hāpai i ka hoʻonui ʻana o nā cell CD4 + T allogeneic a me nā cell CD8 + T. Nui nā polysaccharides mai nā kumu kūlohelohe he hana immunomodulatory maikaʻi loa, e like me nā polysaccharides mai nā halo shiitake, nā halo gill split, nā halo Yunzhi, a me Poria cocos, i hoʻohana ʻia i ka hana lapaʻau. Hiki iā lākou ke hoʻomaikaʻi maikaʻi i ka hana pale ʻana o ke kino, hoʻonui i ka pale ʻana, a lawelawe ma ke ʻano he adjuvant therapy no ka mālama anti-tumor. Eia nō naʻe, liʻiliʻi nā hōʻike noiʻi ma ka PFC ma ke ʻano he modulator immune kanaka. No laila, ke alakaʻi nei kēia ʻatikala i ka noiʻi mua e pili ana i ke kuleana a me nā hana pili o PFC i ka hoʻolaha ʻana i ka oʻo ʻana o nā moDC, i mea e loiloi ai i ka hiki o ka PFC ma ke ʻano he modulator kūlohelohe kūlohelohe.

Ma muli o ka haʻahaʻa haʻahaʻa loa o nā DCs i loko o nā ʻiʻo kanaka a me ke kiʻekiʻe o ka mālama ʻana i waena o nā ʻano ʻano ma waena o nā kiʻi DC a me nā DC kanaka, i mea e hoʻoponopono ai i nā pilikia noiʻi i hoʻokumu ʻia e ka haʻahaʻa DC haʻahaʻa, in vitro induction models o DCs i loaʻa mai nā pūnaewele mononuclear koko peripheral kanaka. ua aʻo ʻia, hiki ke loaʻa nā DC me ka immunogenicity maikaʻi i ka manawa pōkole. No laila, ua hoʻohana kēia haʻawina i ke ʻano kuʻuna o ka hoʻoulu ʻana i nā DCs kanaka i loko o ka vitro: co culturing rhGM CSF a me rhIL-4 in vitro, hoʻololi i ka medium i kēlā me kēia lā, a loaʻa i nā DCs ʻole i ka lā 5; Ma ka lā 6th, ua hoʻohui ʻia nā helu like o PBS, PFC, a me LPS e like me ka hui ʻana a me ka moʻomeheu no nā hola 24 e like me ke kaʻina moʻomeheu no ka hoʻoulu ʻana i nā DC i loaʻa mai nā pūnaewele mononuclear koko peripheral kanaka.

ʻO nā polysaccharides i loaʻa mai nā huahana kūlohelohe nā mea maikaʻi o ka haʻahaʻa haʻahaʻa a me ke kumu kūʻai haʻahaʻa e like me ka immunostimulants. Ma hope o nā hoʻokolohua mua, ua ʻike kā mākou hui noiʻi ua hoʻonui nui ʻo PFC i ka marker CD83 ma luna o ka ʻili o ke kanaka peripheral blood mononuclear cell-derived DC cell in vitro. Hōʻike nā hualoaʻa cytometry i ka hoʻopili ʻana o ka PFC ma kahi ʻano o 10 μg / mL no nā hola 24 i hopena i kahi hōʻike kiʻekiʻe o ka marker oʻo CD83 ma ka ʻili o DCs, e hōʻike ana ua komo nā DC i kahi kūlana makua. No laila, ua hoʻoholo kā mākou hui noiʻi i ka in vitro induction and intervention plan. ʻO CD83 kahi biomarker koʻikoʻi ma luna o ka ʻili o nā DC, ʻoiai ʻo CD86 e lawelawe ma ke ʻano he mole koʻikoʻi co stimulatory ma ka ʻili o DCs, e hana ana ma ke ʻano he hōʻailona lua no ka hoʻōla ʻana i nā cell T. ʻO ka hōʻike hoʻonui ʻia o nā biomarkers ʻelua CD83 a me CD86 e hōʻike ana i ka PFC e hoʻoikaika i ka maturation o ke kanaka peripheral blood mononuclear cell-derived DCs, e hōʻike ana e hiki i ka PFC ke hoʻonui i ka pae huna o nā cytokines ma ka ʻili o DCs. No laila, ua loiloi kēia haʻawina i nā pae o nā cytokines IL-6, TNF-a, a me IL-10 i hūnā ʻia e DC me ka hoʻohana ʻana i ka ELISA. Pili loa ka IL-10 i ka hoʻomanawanui ʻana o nā DCs, a ʻo nā DC me ka hoʻomanawanui ʻole ke hoʻohana mau ʻia i ka mālama ʻana i ka maʻi tumora, e hāʻawi ana i nā manaʻo lapaʻau kūpono no ka hoʻomanawanui ʻana i ka hoʻololi kino; He kuleana koʻikoʻi ka ʻohana 1L-6 i loko o ke kino a me ka adaptive immunity, hematopoiesis, a me nā hopena anti-inflammatory; Aia nā haʻawina e hōʻike ana i ka hui pū ʻana o IL-6 a me TGF β i ka hoʻokaʻawale ʻana o nā cell Th17; Ke hoʻouka ʻia ke kino e kahi maʻi, ʻo ka TNF-a i hana ʻia e DCs i pane i ka hoʻōla ʻana i ka maʻi maʻi ma ke ʻano he kumu hoʻomaʻamaʻa autocrine e hāpai i ka maturation DC. ʻO ka pale ʻana iā TNF-a e hoʻokomo i nā DC i kahi pae ʻole, e pale iā lākou mai ka hoʻokō piha ʻana i kā lākou hana hōʻike antigen. ʻO kaʻikepili ELISA i loko o kēia haʻawina i hōʻikeʻia ua hoʻonui nuiʻia ka pae huna o IL-10 i loko o ka hui PFC i ka hoʻohālikelikeʻana i nā huiʻelua'ē aʻe, e hōʻike ana i ka hoʻonuiʻana o ka PFC i ka palekana palekana o DCs; ʻO ka piʻi ʻana o nā pae huna o IL-6 a me TNF-a e hōʻike ana e loaʻa paha i ka PFC ka hopena o ka hoʻonui ʻana i ka DC e hoʻolaha i ka ʻokoʻa cell T.